Assessment of Bone Tumor Burden Using 68Ga-PSMA PETCT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving 223Ra Therapy

What this Trial Is About

Researchers are evaluating the effectiveness of two diagnostic imaging methods, 68Ga-PSMA PET and Bone Scan, in detecting the progression of metastatic castration-resistant prostate cancer mCRPC in men aged 40 to 85. The study aims to compare how often each imaging tool identifies cancer progression and to explore relationships between PET tumor burden and certain blood markers. This is an open-label, single-arm clinical trial sponsored by Chang Gung Memorial Hospital. Participants will receive intravenous injections of a radioactive tracer called Ga68-PSMA-11, followed by PETCT scans performed on a specialized imaging system. Each participant undergoes a baseline PETCT scan before treatment and additional scans after the third and sixth injections of 223Ra-dichloride therapy. Bone scans are also done for comparison. The imaging and diagnostic results will be analyzed to assess differences in lesion detection between the two methods. During the study, participants will have blood tests, EKGs, and biochemistry assessments before and after their first PET scan. They will be monitored for any adverse events immediately following imaging. Experienced nuclear medicine physicians will interpret all images. The main outcome measured is the change in the number of detected lesions on PET imaging at approximately 9 to 23 weeks. Participants will be observed throughout the study, which continues until August 2025.

68Ga-PSMA PET/CT for Ra223 Assessment